Inspiremd announces strategic agreement with jacobs institute to execute early feasibility study of cguard eps for the treatment of acute stroke patients with tandem lesions

Tel aviv, israel and miami, nov. 27, 2023 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) for the prevention of stroke, today announced that the company has entered into a strategic agreement with the jacobs institute at the state university of new york at buffalo, and dr. adnan siddiqui, vice-chairman and professor of neurosurgery, to execute an early feasibility study (efs) evaluating the cguard eps carotid stent to treat severe carotid stenosis or occlusion, in conjunction with thrombectomy, in patients presenting with acute ischemic stroke and tandem lesions. marvin slosman, chief executive officer of inspiremd, stated, “this early feasibility study provides the appropriate platform for our investment in this indication to address carotid lesions in acute stroke settings and reinforces our commitment to the neuro community, as we aim to demonstrate that cguard eps is optimally designed with a low metal surface and micronet™ mesh covering for superior embolic protection during these acute events.
NSPR Ratings Summary
NSPR Quant Ranking